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Abstract
Background: Chronic fatigue syndrome (CFS) is a complex, multi-symptom illness with a multisystem pathogenesis
involving alterations in the nervous, endocrine and immune systems.
Abnormalities in stress responses have been identified as potential triggers or mediators of CFS symptoms. This
study focused on the stress mediator neuropeptide Y (NPY). We hypothesized that NPY would be a useful
biomarker for CFS.
Methods: The CFS patients (n = 93) were from the Chronic Fatigue and Related Disorders Clinic at the University
of Miami and met the 1994 case definition of Fukuda and colleagues. Healthy sedentary controls (n = 100)) were
from NIH or VA funded studies. Another fatiguing, multi-symptom illness, Gulf War Illness (GWI), was also compared
to CFS. We measured NPY in plasma using a radioimmunoassay (RIA). Psychometric measures, available for a subset
of CFS patients included: Perceived Stress Scale, Profile of Mood States, ATQ Positive & Negative Self-Talk Scores,
the COPE, the Beck Depression Inventory, Fatigue Symptom Inventory, Cognitive Capacity Screening Examination,
Medical Outcomes Survey Short Form-36, and the Quality of Life Scale.
Results: Plasma NPY was elevated in CFS subjects, compared to controls (p = .000) and to GWI cases (p = .000).
Receiver operating characteristics (ROC) curve analyses indicated that the predictive ability of plasma NPY to
distinguish CFS patients from healthy controls and from GWI was significantly better than chance alone. In 42
patients with CFS, plasma NPY had significant correlations (<0.05) with perceived stress, depression, anger/hostility,
confusion, negative thoughts, positive thoughts, general health, and cognitive status. In each case the correlation
(+ or -) was in the anticipated direction.
Conclusions: This study is the first in the CFS literature to report that plasma NPY is elevated compared to healthy
controls and to a fatigued comparison group, GWI patients. The significant correlations of NPY with stress, negative
mood, general health, depression and cognitive function strongly suggest that this peptide be considered as a
biomarker to distinguish subsets of CFS.
Background
According to the 1994 international research case defi-
nition [1], as modified according to Reeves, et al [2],
chronic fatigue syndrome (CFS) is an illness character-
ized by 1) the presence of persisting, debilitating fatigue
that does not resolve with bed rest, and lasts for at least
six months resulting in severe impairment in daily func-
tion; 2) by symptoms and disability that cannot be
ascribed to any other medical and psychiatric condi-
tions. Diagnosis relies in large part on behavioral mar-
kers, either patients’ self-reported symptoms or
observations by clinicians. Laboratory diagnostic and
screening tests are not widely available.
In 60 to 80% of published samples, CFS presented
with acute onset of illness, with systemic symptoms
similar to influenza infection that did not subside [3].
The sudden onset, the symptoms of myalgia, arthralgia,
sore throat and tender lymphadenopathy support the-
ories of infection induced illness [3,4]. Published reports
both confirm and deny associated microbial infections,
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any medium, provided the original work is properly cited.reactivation of latent herpes virus infections and/or ret-
rovirus infections in CFS [5-14].
CFS is responsible for significant morbidity and occurs
in an estimated 0.42% of people, predominately female,
in the United States and worldwide [15,16]. Prior work
strongly suggests this complex, multi-symptom illness
has a multi-system pathogenesis that involves the ner-
vous, endocrine and immune systems [3,17-21]. Abnorm-
alities in stress responses have been identified as
potential triggers or mediators of CFS symptoms [22-24].
Neuropeptide Y (NPY) is found in both the central
and peripheral nervous systems. In the peripheral ner-
vous system, NPY is concentrated in and released from
sympathetic nerve endings, either alone or with catecho-
lamines. Irwin reported NPY increased in depressed and
stressed subjects, and suggested that “circulating levels
of this neuropeptide serves as a tonic measure of sympa-
thetic activity” [25]. NPY release follows stress such as
strenuous exercise [26], panic disorders [27], and cold
exposure [28]. In the periphery, NPY is activating and
stimulates the stress response, but in the brain, NPY is
anxiolytic, inhibitory of sympathetic activity and causes
lowering of blood pressure and heart rate [29,30]. Con-
centrations of NPY in the brain are higher than other
neuropeptides, particularly in the limbic system, includ-
ing the amygdala and the hypothalamus, all areas of the
brain involved with emotion [31,32].
Plasma levels of NPY are reported to be elevated in
other complex multi-symptom illnesses associated with
immunologic dysfunction, including rheumatoid arthritis
(RA) and systemic lupus erythematosus (SLE) [33]. A
recent study compared 51 fibromyalgia patients to 25
healthy controls and reported elevated plasma NPY [34].
However, an earlier study found lower NPY in 12 fibro-
myalgia cases [35]
Given these reports, it seemed likely that plasma NPY
would be elevated in CFS. Elevated NPY would be antici-
pated to correlate with psychological measures of stress
and other aspects of CFS symptoms. However, we could
find no such studies. There is a clear need for CFS bio-
markers that are useful in diagnosis, in defining patient
subgroups and in therapeutic trials. We tested and con-
firmed the hypotheses that elevation of peripheral NPY
occurs in CFS and that elevation of NPY is associated with
severity of stress, negative mood and clinical symptoms.
Methods
Objectives
Abnormalities in stress responses have been identified as
potential triggers or mediators of CFS symptoms. This
study focused on the stress mediator neuropeptide Y
(NPY). The aim was to examine the potential of plasma
NPY as a biomarker for stress and symptom severity
in CFS.
Participants
All subjects were participants in research studies taking
place between 2002 to 2010 at the University of Miami
or the Miami Veterans Administration Health Care
Center (funded by NIH, VA, Chronic Fatigue and
Immunodeficiency Syndrome Association or the Univer-
sity of Miami).
Chronic fatigue syndrome patients (n = 93; age 18 to 60,
mean age 44 +/- 9 S.D.; median age 46, 25 percentile 38,
75 percentile 50; 83% female) were drawn from the
University of Miami Miller School of Medicine CFS and
Immunodeficiency Clinic after they were diagnosed with
CFS, using the 1994 international research case definition
[1], as modified according to Reeves, et al [2]. This
requires 4 of 8 symptoms including exercise induced
relapse, myalgia, arthralgia, headache of a new and differ-
ent type, nonrestorative sleep, cognitive complaints, sore
throat and tender lymph nodes. Exclusion criteria included
any active medical condition that could explain the pre-
sence of chronic fatigue, including diabetes, the current
use of immunomodulatory or antibiotic medications, and
a past or present psychiatric diagnosis of psychosis (e.g.,
schizophrenia), dementia, major depressive disorder with
psychotic or melancholic features, bipolar disorder, anor-
exia or bulimia nervosa, or alcohol/substance abuse disor-
der within two years of the onset of the fatigue or anytime
thereafter. In agreement with published samples, the
majority of CFS cases presented with a history of acute
onset of illness, with systemic symptoms similar to influ-
enza infection that did not subside [4].
Sedentary healthy controls, with no active medical or
psychiatric conditions, immunomodulating medications
or alcohol/substance abuse, (n = 100; 84% female; mean
age 41 +/- 10 S.D.; median age 41, 25 percentile 35, 75
percentile 49) were from NIH or VA funded studies con-
ducted by one or more of the investigators in this study.
A comparison group of patients with a fatiguing,
multi-symptom illness, GWI, was also included in the
study (N = 37; 29% female, mean age 44 +/- 7; median
age 42, 25 percentile 38, 75 percentile 48). The inclusion
criteria for GWI, derived from the case definition by
Fukuda et al [36], was: a veteran deployed to the theater
of operations for Operation Desert Storm between
August 8, 1990 and July 31, 1991 with one or more
symptoms present greater than 6 months from at least 2
of the following: fatigue; mood and cognitive complaints;
and musculoskeletal complaints (joint pain, stiffness or
muscle pain). These subjects had no active medical or
psychiatric conditions, immunomodulating medications
or alcohol/substance abuse.
Blood collection
Morning, non-fasting blood samples were collected, prior
to the collection of clinical or and psychometric data.
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acid and all of the samples for this study were delivered to
University of Miami clinical immunology laboratory within
2 hours. The laboratory received and assayed the samples
in a blinded fashion. Plasma was separated from cells
within 2 hours of collection, aliquoted into cryovials and
stored at - 80°C until assayed. The length of time of sto-
rage at -80°C varied from 6 months to 5 years for the sam-
ples in this study. Samples were thawed only one time.
Assay of NPY
Plasma NPY was measured by direct assay without
extraction using a competitive radioimmunoassay (RIA)
from ALPCO Diagnostics (Salem, NH). The antiserum
was raised against synthetic NPY conjugated to bovine
thyroglobulin and cross-reacted less than 2.0% with
human peptide YY. The NPY in standards and samples
competed with
125I-labeled NPY in binding to the
antibody.
125I-NPY bound in reverse proportion to the
concentration of NPY in standards and samples. Anti-
body-bound
125I-NPY was separated from the unbound
fraction with a double antibody coupled to the solid
phase. The radioactivity of the antibody-bound
125I-NPY
was then determined. The measurable range of the assay
was 9.4 - 300 pmol/L and sensitivity was 3 pmol/L. The
manufacturer reported a mean value of 74 pmol/L (SD
= ± 15) and a range of 36-120 pmol/L for 109 healthy
controls (ages 20-60 years). The intra assay coefficient
of variation (CV%) was 4.75%. The inter assay CV% was
8.4%. All samples were assayed in duplicate. All assays
were done in the same laboratory. Individual runs were
mixtures of samples from the 3 cohorts in the study.
A set of control samples were included in each assay.
Self report measures of clinical symptoms
On a subset of 42 CFS cases in this study, perceptions
of general health and well-being, severity of clinical
symptoms of fatigue, stress, cognitive difficulties, psy-
chological distress and maladaptive coping were assessed
using the following self-report measures:
￿ The Medical Outcomes Survey Short Form-36 (SF-
36) assessed health-related quality of life including:
limitations in social activities, emotional problems
and general health [37].
￿ The Perceived Stress Scale (PSS) was used as a
measure of stress [38].
￿ T h eF a t i g u eS e v e r i t yI n v e n t o r y( F S I )w a sd e s i g n e d
for measuring fatigue severity. Items in the inventory
are statements related to fatigue perceptions [39].
￿ The COPE, a multidimensional coping inventory,
was used to assess the different ways in which peo-
ple respond to stress [40]. Subscales for denial, beha-
vioral disengagement and self-blame were used.
￿ The Quality of Life Scale (QOL) total score mea-
sured general well-being, cognitive functioning,
affective status, physical health status and social
activity [41].
￿ The Profile of Mood States (POMS) a measure of
psychological distress consists of 65 adjectives rated
on a 0-4 scale that are comprised of subscales mea-
suring ‘depression-dejection’, ‘tension-anxiety’,
‘anger-hostility’, ‘confusion-bewilderment’, ‘vigor-
activity’ and ‘fatigue-inertia’ [42].
￿ The Adult Temperament Questionnaire (ATQ) is a
7 7 - i t e ms e l f - r e p o r ti n s t r u m e n tu s e df o ra s s e s s m e n t
of positive and negative thoughts and is a measure
of stress that is possibly predictive of stress-related
health problems [43].
￿ The Cognitive Capacity Screening Examination
(CCSE) was used to quantify the general cognitive
status of subjects [44].
￿ The Beck Depression Inventory (BDI) is a 21-ques-
tion multiple-choice self-report inventory used to
measure severity of depression [45].
These instruments were completed by the CFS
patients on the same visit as the blood draw.
Ethics statement
T h i ss t u d yw a sa p p r o v e db yt h eU n i v e r s i t yo fM i a m i
Institutional Review Board. All subjects signed a written
informed consent approved by the University of Miami
Institutional Review Board. All consented to blood draw
and to the availability of the stored samples for addi-
tional bioassays. Participants were English speaking with
at least an 8th grade education to ensure they were able
to comprehend the informed consent as well as read
and complete the questionnaires.
Statistical methods
The Mann-Whitney U test was used to determine the
magnitudes of between-group (case-control) differences.
Pearson correlations were calculated for the psychoso-
cial measures of disease severity and plasma NPY in 42
CFS cases. Values of p < 0.05 were considered statisti-
cally significant. The diagnostic accuracy of NPY was
assessed in terms of true positive (sensitivity) versus
true negative (1-specificity) using nonparametric receiver
operating characteristics (ROC) analyses [46] available in
the Statistical Package for Social Sciences (SPSS) soft-
ware for Windows (SPSS Inc, Chicago, IL). The non-
parametric ROC plot uses all of the data, makes no
parametric assumptions and provides unbiased estimates
of sensitivity and specificity, indicating the ability of a
test to discriminate between two alternate states of
health, in this case, CFS cases and healthy controls and
CFS cases and GWI cases. The calculation of the area
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d e t e r m i n et h ea b i l i t yo ft h eN P Ya s s a yt od i s t i n g u i s h
these groups. An AUC = 0.5 indicates that the test
shows no difference between the two groups while AUC
= 1.0 is found if the test gives a perfect separation
between groups.
Results
Plasma NPY (pmol/L) was elevated in CFS subjects,
compared to controls (mean for CFS patients = 102.4
+/-49.2, mean for controls = 79.8 +/-34.9, p = .000).
CFS cases were also elevated when compared to GWI
cases (mean for GWI patients = 75.1 +/- 38.1, p = .000).
The distribution of plasma NPY values for the CFS
cases, the healthy controls and for GWI are shown in
Figure 1. ROC curve analyses of CFS and controls indi-
cated that the predictive ability of plasma NPY was sig-
nificantly better than chance alone (see Figure 2,
Table 1). ROC curve analysis showed that NPY also dis-
tinguished GWI from CFS (Figure 3, Table 2). The
coordinates of the curves (COC)) provide the entire
spectrum of sensitivity/specificity pairs and a complete
picture of test accuracy (see Additional files 1 and 2).
For 42 patients in this study we had both NPY and
the results of a battery of clinical self report measures
(Table 3). The plasma NPY had significant Pearson cor-
relations with a variety of self report measures of symp-
tom severity, including stress, negative mood and
general health, and mental status in patients with CFS.
The peptide also had Pearson correlations of p < 0.1
with measures of quality of life, vigor, emotional well-
being, social functioning and fatigue disruption rating.
In each case the correlation (+ or -) was in the antici-
pated direction. The demographic data for these 42
cases are shown in Table 4. The plasma NPY in this
subset of CFS patients was elevated in comparison to
healthy controls (p = .04) and to GWI cases (p = .05)
Discussion
In this study, we found that the stress hormone, NPY,
was statistically elevated in plasma from CFS cases com-
pared to healthy controls - and to a group of patients
with another fatiguing, multi-symptom illness, GWI.
This later finding was unexpected. However, it might be
explained by gender distribution, which was very differ-
ent between CFS and GWI. ROC analysis indicated that
plasma NPY has promise as a biomarker for distinguish-
ing CFS both from healthy controls and .from related
fatiguing illnesses. Our finding that NPY positively cor-
related with perceived stress, anger, depression, negative
thoughts and maladaptive coping in patients with CFS
suggests that NPY will be useful in defining subsets of
patients for clinical trials and as a measure of therapeu-
tic effects.
Figure 1 The panels show the histogram of plasma NPY values
for the Chronic Fatigue Syndrome cases (CFS), the healthy
controls (HC) and the Gulf War Illness cases (GWI).
Figure 2 ROC curve analyses of plasma NPY (red curve) as a
predictor of CFS, comparing CFS with healthy controls. Larger
values were associated with CFS cases. The 45 degree line (green)
indicates the theoretical plot of a test with no discrimination
between CFS and controls.
Table 1 Area Under the Curve (AUC): NPY in Plasma
Comparing CFS and HC









.655 .040 p < .000 .577 .733
aUnder the nonparametric assumption.
bNull hypothesis: true AUC = 0.5.
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gers or mediators of CFS symptoms [4]. Acute stress
induces a fight-and-flight response that prepares the
organism for coping with environmental challenge [47].
Sympathoadrenal activation during the stress response
results in increased release of epinephrine (E) and nore-
pinephrine (NE) from the adrenal medulla, increased
NE and NPY release from the sympathetic nerve end-
ings and changes in blood flow to a variety of organs
[48]. Activation of the hypothalamic-pituitary-adrenal
(HPA) axis results in increased secretion of glucocorti-
coids from the adrenal cortex [49].
Glucocorticoids regulate immune cell reactions to the
stressor. In the brain, stress responsive neurotransmitter
systems, in interaction with glucocorticoids, modulate
affect, cognition and anxiety, and suppress behaviors
that are inadequate for the situation, such as eating and
reproduction. Increased noradrenergic activity in the
brainstem increases vigilance and alertness and pro-
motes memory for threatening stimuli [50]. These acute
stress responses represent regulatory mechanisms that
are critical to survival and adaptation of the species.
Dysfunction in the regulatory capacity or interplay of
these systems, as a potential consequence of disposi-
tional risk or physical, chemical or emotional challenges,
might plausibly exacerbate symptoms of CFS.
Immune activation and inflammation are postulated
to be principle components in the pathophysiology of
CFS [19,20,51]. Inflammatory responses are controlled
by the HPA axis network that involves corticotropin-
releasing hormone (CRH), adrenocorticotropic hor-
mone (ACTH) and cortisol. Normally cortisol induces
a down-regulation of inflammation. However, this
mechanism is disrupted in the typically hypocortisolic
CFS patient [52]. Broderick and colleagues propose
that this disruption results not only from the possible
failure of individual neuro-immune components but
also involves a spontaneous restructuring of the con-
trol network [21]. Van Houdenhove and co-workers
have formulated the hypothesis that the HPA axis
hypofunction in CFS reflects a fundamental and persis-
tent dysregulation of the neurobiological stress system
[53]. Dysautonomic conditions (e.g., neurally mediated
hypotension or orthostatic intolerance) have been
reported in CFS patients as well as the related syn-
drome, GWI [54,55].
Figure 3 ROC curve analyses of plasma NPY (blue curve) as a
predictor of CFS, comparing CFS with GWI. Larger values were
associated with CFS cases. The 45 degree line (green) indicates the
theoretical plot of a test with no discrimination between CFS
and GWI.
Table 2 Area Under the Curve (AUC): NPY in Plasma
Comparing CFS and GWI






a Lower Bound Upper Bound
.666 .053 p < .003 .561 .771
a. Under the nonparametric assumption.
b. Null hypothesis: true area = 0.5.
Table 3 Pearson Correlations (with p < 0.1) of
Measurements Reflective of Symptom Severity and
Plasma Neuropeptide Y in CFS cases




BECK Depression Inventory 42 .285* .068
FSI Disruption Rating 42 .286* .066
POMS Anger/Hostility Subscale 41 .490*** .001




POMS Friendly Subscale 42 -.562*** .000
POMS Vigor Subscale 42 -.294* .059




Cope: Self Blame 42 .315** .042
ATQ Negative Self-Talk Score 42 .307** .048
ATQ Positive Self-Talk Score 42 -.315** .042
Perceived Stress Scale Total
Score
42 .414*** .006
Quality of Life Total Score 42 -.297* .056
SF-36 General Health 42 -.377** .014
SF-36 Emotional Well-Being 42 -.264* .091
SF-36 Social Functioning 41 -.281* .075
CCSE-R Total Score 42 -.330** .033
*p > .10; **p < .05; ***p < .01
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stroke volume and cardiac output in more severely
afflicted CFS patients [56]. Although we did not mea-
sure cortisol in the present study, we and others
reported that moderate hypocortisolism occurs in CFS,
and that it is of clinical relevance [57,58]. For example,
CFS cases with low cortisol have a poorer response of
CFS cases to cognitive behavioral stress management
[58]. Of interest is the finding of Kempna, et al. [59],
that NPY inhibits the production of cortisol in human
adrenal H295R cells via the Y1 receptor. Antonijevic
and colleagues showed that administration of NPY
reduced cortisol secretion during night hours in healthy
subjects [60]. In contrast, a series of experiments by
Morgan, et al. demonstrated that acute, uncontrollable
psychological stress elevated plasma NPY as well as
plasma cortisol in healthy subjects [61,62].
Recently, our group reported that soluble as well as
cell surface associated dipeptidyl peptidase IV (DPPIV)
is decreased in CFS cases relative to controls [20].
NPY’s biologic effects require interaction with its recep-
tors. Native NPY 1-36 in the periphery is a major
mediator of stress, responsible for prolonged vasocon-
striction via Y1 receptors [29]. By cleaving the N-term-
inal Tyr-Pro dipeptide from NPY, DPPIV generates the
Y2/Y5 receptor agonist NPY 3-36, that loses its affinity
for the Y1 receptor and is angiogenic and inhibitory of
NE release [30,63]. The low DPPIV observed in CFS
coupled with high NPY would favor the Y1 receptor
agonist form of NPY.
Another consideration of interest regarding NPY and
CFS is the possibility of chronic viral infection in some
patients. Du, et al [64], recently described increased
NPY expression in the central nervous system (CNS) of
mice following infection with a neurovirulent polytropic
retrovirus. This virus infects macrophages and microglial
cells resulting in production of proinflammatory cyto-
kines [65], including interleukin 1 alpha (IL-1a), IL-b,
and Il-6 known to be elevated in CFS [19]. Viral triggers
such as EBV and HHV6 have long been suspected of
involvement in the onset and persistence of CFS [3,5,6].
Evidence of xenotropic murine leukemia virus - related
virus (XMRV) in peripheral blood mononuclear cells
(PBMCs) in the majority of CFS cases, but not controls,
supported the viral infection hypothesis [11]. This report
by Lombardi, et al was followed by 4 subsequent reports
of failure to detect any murine leukemia virus (MLV)-
related virus gene sequences in blood from CFS patients
[12,14,66,67] and one report of MLV-like virus gag gene
sequences, but not XMRV, in 86.5% CFS cases com-
pared with only 6.8% of healthy volunteer blood donors
[13].
Limitations
An obvious limitation of this study is that the samples
represent a single point in time. We are presently con-
ducting longitudinal studies. As Broderick and collea-
gues have pointed out, biomarkers measured in human
subjects tend to be highly variable. These indicators are
parts of a complex and integrated system and their
inter-dependency must be addressed. The effect of med-
ications such as cholesterol lowering, pain or anti-
depression on plasma NPY is not known. However,
cholesterol-lowering drugs are not well tolerated in CFS
patients. Patients on opioid pain medications were
excluded from the study. The effect storage of plasma
for up to 5 years at -80°C on RIA detectible NPY is not
known.
Conclusions
This study is the first in the CFS literature to report that
plasma NPY is significantly elevated over healthy con-
trols and also over a comparision group, patients with
GWI. The elevation of NPY inC F Sc a s e si sa s s o c i a t e d
with severity of stress, negative mood and clinical symp-
toms. The pattern, in some CFS cases, of high NPY
noted here, along with previously observed low DPPIV
and hypocortisolism [20,57,58] supports the hypothesis
of HPA axis dysregulation in CFS. Duration of this ill-
ness typically exceeds 10 years. Persistence is likely to
involve complex interaction of immune, autonomic and
neuroendocrine regulation and remains poorly under-
stood. Investigation of CFS biology has focused on the
detailed characterization of individual neuroendocrine
and immune components taken in isolation. Current
CFS treatments are directed at reducing symptom sever-
ity but no cure exists for this condition. In a review of
CFS, published in Lancet, Prins, et al. stated: “Techni-
ques such as bioimaging and proteomic strategies, and
perhaps a systems biology approach, should be applied
to try to elucidate such complicated interactions” [68].
It is clear that further understanding of disease mechan-
isms and development of effective treatments will
require more than a list of the abundance of gene pro-
ducts, proteins or cells. These various cellular and mole-
cular components are highly inter-dependent. Our
Table 4 Description of CFS Cases in Table 3
Female Plasma Age Age Time since onset Time since onset of Sudden onset of
(%) NPY(mean pmol/L +/- SD) (range) (mean) of symptoms (range) symptoms (mean +/- SD) symptoms (%)
90% 97.4 +/- 31.2 23 - 60 years 46 years 1 - 38 years 12 +/- 8 years 66%
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approach [69]. We are presently incorporating data
from plasma NPY measurements, along with other
plasma and cellular biomarkers into a network analysis.
The renewed interest in viral infections in CFS sug-
gests further studies. It is possible that NPY is induced
by such infections. As reliable assays become available it
will be important to determine the relationship of
plasma NPY to potential pathogens.
Additional material
Additional file 1: Coordinates of the Curve CFS and HC. The
coordinates of the curves (COC) provide the entire spectrum of
sensitivity/specificity pairs and a complete picture of test accuracy.
Additional file 2: Coordinates of the Curve CFS and GWI. The
coordinates of the curves (COC) provide the entire spectrum of
sensitivity/specificity pairs and a complete picture of test accuracy.
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